Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11285181-B2
Publication Date
2022-03-29
Expiration Date
Abstract
The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
Core Innovation
The disclosed invention concerns lactic acid bacteria, particularly Lactobacillus reuteri strains DSM 27131 and DSM 32465, that utilize ethanolamine. Ethanolamine utilization enables competition with ethanolamine-utilizing pathogens by shared substrate use, thereby reducing pathogen growth and/or virulence.
The document further links ethanolamine utilization to antimicrobial effects, including effects attributable to acetaldehyde. DSM 27131 and DSM 32465 produce acetaldehyde in an agar assay, while Lactobacillus reuteri DSM 17938 is negative for acetaldehyde production in the described assay.
The disclosure also describes identification and selection approaches for ethanolamine-utilizing strains, including genetic profiling using markers such as eutB, eutL, and eutH, with optional pfam03358 and/or pfam13350 homologues. It also describes inducing and/or producing ethanolamine-utilizing bacteria by culturing with ethanolamine, and reports strain-dependent properties such as improved bile tolerance for DSM 32465 versus DSM 27131 and strong inhibition of ex vivo growth of C. difficile by DSM 27131.
Claims Coverage
The provided independent claims include four inventive features.
Frozen and/or lyophilized probiotic composition of DSM 27131 with cryo/lyoprotectants
A composition comprising frozen and/or lyophilized probiotic Lactobacillus reuteri DSM 27131 and one or more of a cryoprotectant and/or a lyoprotectant.
Biologically pure culture of DSM 32465
A biologically pure culture of Lactobacillus reuteri DSM 32465.
Probiotic composition of DSM 32465 with cryo/lyoprotectants
A composition comprising probiotic Lactobacillus reuteri DSM 32465 and one or more of a cryoprotectant and/or a lyoprotectant.
Treating or reducing the risk from ethanolamine-utilizing pathogens using DSM 32465 and/or DSM 27131
A method for treating or reducing the risk of developing a condition or disorder caused by or related to an ethanolamine-utilizing pathogen in a subject, comprising administering an effective amount of a composition comprising Lactobacillus reuteri DSM 32465 and/or Lactobacillus reuteri DSM 27131.
Across the independent claims, the claim coverage includes probiotic compositions and cultures based on Lactobacillus reuteri DSM 27131 and DSM 32465, including formulations using cryoprotectants and/or lyoprotectants, and a method of treating or reducing risk of disorders associated with ethanolamine-utilizing pathogens via administration of DSM 32465 and/or DSM 27131.
Stated Advantages
Reduces pathogen growth and/or virulence by competing with ethanolamine-utilizing pathogens through shared substrate use.
Provides antimicrobial effects associated with acetaldehyde.
Improves bile tolerance for Lactobacillus reuteri DSM 32465 versus Lactobacillus reuteri DSM 27131.
Strongly inhibits ex vivo growth of C. difficile by Lactobacillus reuteri DSM 27131.
Documented Applications
Treatment or risk reduction of a condition or disorder caused by or related to an ethanolamine-utilizing pathogen in a subject.
Disorders and conditions explicitly linked to ethanolamine-utilizing pathogens include dysbiosis, listeriosis, salmonellosis, inflammatory bowel disorders, infected wounds with pathogenic pseudomonades, and tourist diarrhea.
GI-context use is described for example treatment/prophylaxis conditions associated with ethanolamine-utilizing pathogens.
Interested in licensing this patent?